Effect of cisplatin on proteasome activity

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• Cisplatin is a cornerstone chemotherapy agent with known cytotoxic effects via nuclear and cytosolic pathways.
• The proteasome is a critical cellular complex responsible for protein degradation and homeostasis.

Purpose of the Study:

• To investigate the effect of cisplatin on proteasome activity.
• To explore the combined effect of cisplatin and proteasome inhibitor lactacystin on cancer cell cytotoxicity.

Main Methods:

• In vitro assays measuring the three enzymatic activities of the proteasome (chymotrypsin-like, trypsin-like, caspase-like).
• Administration of cisplatin to neuroblastoma cells to assess proteasome activity and synthesis.
• Combination treatment of neuroblastoma cells with cisplatin and lactacystin.

Main Results:

• Cisplatin demonstrated a dose-dependent inhibition of all three major proteasome enzymatic activities in vitro.
• Cisplatin treatment led to rapid loss of proteasome activity in neuroblastoma cells, followed by de novo proteasome synthesis.
• Co-administration of lactacystin and cisplatin significantly enhanced the cytotoxicity of cisplatin alone.

Conclusions:

• Cisplatin possesses a novel inhibitory effect on proteasome activity, independent of its genotoxic effects.
• Targeting the proteasome pathway in conjunction with cisplatin may represent a promising strategy for enhancing chemotherapy efficacy.
• These findings expand the understanding of cisplatin's biological mechanisms beyond DNA damage.